EP 3 167 888 B1 relates to the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by an inhibitor of complement. The product is known as eculizumab.
It stems from a third generation divisional of EP 2 359 834 A1 and EP 2 001 490 A1 filed as PCT/US2007/006606 and published under WO 2007/106585
Brief outline of the procedure before the EPO
Proprietor is Alexion Pharmaceuticals,